Literature DB >> 4343412

Antiviral immune cytolysis at an early stage of paramyxovirus infection.

M D Eaton, A R Scala.   

Abstract

Antiviral antibody and rabbit complement added as early as 5 min after infection, and with relatively low virus/cell multiplicity, lysed mouse ascites lymphoma cells infected with Sendai or Newcastle disease virus. Inactive Sendai virus at much higher input also sensitized ascites cells and mouse fibroblast monolayers to early antiviral immune cytolysis. At 4 C where adsorption but no penetration occurred, antibody removed virus from the cell membrane and little cytolysis was observed. The ascites cells were sensitive to antibody and complement at all times after the start of penetration and uncoating, indicating that viral envelope antigen is constantly present on the cell membrane. Significant cross-reactions by immune cytolysis between Newcastle disease virus- and Sendai virus-infected cells suggested possible participation of host antigens of the viral envelope. No comparable antiviral immune cytolysis was observed with influenza strains PR8 and WSN. Cell viability was estimated by dye exclusion and the ability to form acid from glucose as indicated by colorimetric pH of the medium. The relation of antiviral immune cytolysis to changes in the membrane resulting in cell fusion is considered.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4343412      PMCID: PMC416364          DOI: 10.1128/iai.4.5.642-649.1971

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Further observations on the inhibitory effect of myxoviruses on a transplantable murine leukemia.

Authors:  M D Eaton; A R Scala
Journal:  Proc Soc Exp Biol Med       Date:  1969-10

2.  Species source of complement in viral-immune and other cytolytic reactions.

Authors:  M D Eaton; A R Scala
Journal:  Proc Soc Exp Biol Med       Date:  1970-02

3.  A comparison of immune cytolysis and virus-induced fusion of sensitive and resistant cell types.

Authors:  K V Holmes; H D Klenk; P W Choppin
Journal:  Proc Soc Exp Biol Med       Date:  1969-06

4.  Structure and development of viruses as observed in the electron microscope. IX. Entry of parainfluenza I (Sendai) virus.

Authors:  C Morgan; C Howe
Journal:  J Virol       Date:  1968-10       Impact factor: 5.103

5.  Poliovirus replication and cytopathogenicity in monolayer hamster cell cultures fused with beta propiolactone-inactivated Sendai virus.

Authors:  J M Neff; J F Enders
Journal:  Proc Soc Exp Biol Med       Date:  1968-01

6.  The morphological and biological effects of various antisera on avian infectious bronchitis virus.

Authors:  D M Berry; J D Almeida
Journal:  J Gen Virol       Date:  1968-07       Impact factor: 3.891

7.  Preliminary analysis of the requirements for fusion from within and fusion from without by Newcastle disease virus.

Authors:  M A Bratt; W R Gallaher
Journal:  Proc Natl Acad Sci U S A       Date:  1969-10       Impact factor: 11.205

8.  Further observations on the inhibitory action of ammonium chloride on influenza virus.

Authors:  M D Eaton; A R Scala
Journal:  Proc Soc Exp Biol Med       Date:  1967-05

9.  Contribution of antiviral immunity to oncolysis by Newcastle disease virus in a murine lymphoma.

Authors:  M D Eaton; J D Levinthal; A R Scala
Journal:  J Natl Cancer Inst       Date:  1967-12       Impact factor: 13.506

10.  Interactions between Sendai virus and human erythrocytes.

Authors:  C Howe; C Morgan
Journal:  J Virol       Date:  1969-01       Impact factor: 5.103

View more
  2 in total

1.  Cytotoxic antibody activity in measles and subacute sclerosing panencephalitis (SSPE) infection.

Authors:  R Kibler; A Deller; V ter Meulen
Journal:  Med Microbiol Immunol       Date:  1974       Impact factor: 3.402

2.  Persistent parainfluenza type 1 (6/94) infection of brain cells in tissue culture.

Authors:  Z Wroblewska; D Santoli; D Gilden; L Lewandowski; H Koprowski
Journal:  Arch Virol       Date:  1976       Impact factor: 2.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.